Arvinas (ARVN) Other financing activities (2018 - 2022)
Arvinas (ARVN) posted quarterly Other financing activities of $500000.0 for Q4 2022, down 86.84% year-over-year from $3.8 million in Q4 2021, and down 58.33% quarter-over-quarter from $1.2 million in Q3 2022.
Analysis
Arvinas (ARVN) Other financing activities (2018 - 2022) Analysis & Trends
Arvinas' Other financing activities history runs 4 years deep, the most recent figure standing at $500000.0 for Q4 2022.
- In Q4 2022, Other financing activities fell 86.84% year-over-year to $500000.0; the TTM figure through Dec 2022 stood at $4.7 million (down 74.73% YoY), while the FY2022 annual figure was $4.7 million, down 74.73% from the prior year.
- Other financing activities for Q4 2022 stood at $500000.0, down from $1.2 million in the prior quarter.
- The five-year high for Other financing activities was $6.7 million in Q3 2021, with the low at $399488.0 in Q2 2019.
- The 4-year median for Other financing activities is $1.4 million (2020), against an average of $2.3 million.
- The sharpest annual moves came in 2021 and 2022: Other financing activities surged 1060.57% in 2021, then tumbled 86.84% in 2022.
- Arvinas' Other financing activities stood at $1.0 million in 2019, then surged by 398.08% to $5.1 million in 2020, then decreased by 25.39% to $3.8 million in 2021, then sank by 86.84% to $500000.0 in 2022.
- Business Quant data shows ARVN's Other financing activities at $500000.0 in Q4 2022, $1.2 million in Q3 2022, and $500000.0 in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Arvinas | 609.44 Mn | 41.54 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 500,000.00 |
| Sep 30, 2022 | 1.20 Mn |
| Jun 30, 2022 | 500,000.00 |
| Mar 31, 2022 | 2.50 Mn |
| Dec 31, 2021 | 3.80 Mn |
| Sep 30, 2021 | 6.70 Mn |
| Jun 30, 2021 | 3.60 Mn |
| Mar 31, 2021 | 4.50 Mn |
| Dec 31, 2020 | 5.09 Mn |
| Sep 30, 2020 | 577,303.00 |
| Jun 30, 2020 | 1.28 Mn |
| Mar 31, 2020 | 1.35 Mn |
| Dec 31, 2019 | -26.65 Mn |
| Sep 30, 2019 | 29.05 Mn |
| Jun 30, 2019 | 399,488.00 |
| Dec 31, 2018 | 75,000.00 |